

# Taking an In-depth Look at Abemaciclib Clinical Data

Date & Time Sep 22 2019,  
1000-1700  
Venue 3F Amber, Le Meridien Taipei

Time	Theme	Class	Speakers	Chair
0930-1000		Registration		
1000-1005		Opening Remarks	Kynon L Ingram (GM, Lilly Taiwan)	
1005-1055	Plenary	CDK4&6i: change in the paradigm of sequencing and future treatment of HR + / HER2- breast cancer	盧彥伸醫師	曾令民醫師
1055-1140	VERZENIO + Aromatase Inhibitor	MONARCH 3: VERZENIO + Aromatase inhibitor in patients sensitive to endocrine therapy	饒坤銘醫師	
1140-1150		Discussion	Panelists: 曾令民醫師、Dr.Francisco、盧彥伸醫師、饒坤銘醫師	
1150-1300		Lunch		
1300-1350	VERZENIO + Fulvestrant	MONARCH 2: VERZENIO + Fulvestrant in patients resistant to previous endocrine therapy	Dr. Shaheenah Dawood(UAE)	陳達人醫師
1350-1435	VERZENIO in East Asia Patients Population	East Asia patients subgroup analysis in MONARCH3 & MONARCH2	Dr. Hiroji Iwata(Japan)	
1435-1445		Discussion	Panelists: 陳達人醫師、Dr.Dawood、Dr.Iwata	
1445-1455		Break		
1455-1530		MONARCH3 and MONARCH2 subgroup analysis	林季宏醫師	陳訓徹醫師 (邀請中)
1530-1605		MONARCH 1: VERZENIO monotherapy for heavily pre-treated patients who failed endocrine therapy and chemotherapy	趙大中醫師	
1605-1640		Panel Discussion	Panelists:陳訓徹醫師、林季宏醫師、趙大中醫師	陳芳銘醫師
1640-1655		Wrap up	曾令民醫師	
1655-1700		Closing Remarks	陳芳銘醫師	